Thoas Fioretos - Genetic Mutations

Author Information

Dr. Thoas Fioretos is affiliated with the Division of Clinical Genetics, Department of Laboratory Medicine at Lund University in Lund, Sweden. His work primarily focuses on the genetic and molecular aspects of hematological malignancies, particularly acute leukemia.

Research Contributions

Dr. Thoas Fioretos has made significant contributions to the field of genetics and hematological malignancies. His research delves into various aspects of leukemia, including the mechanisms of synthetic lethality for targeting specific leukemic cells, the diagnostic methodologies for leukemia, and the implementation of whole-genome and transcriptome sequencing for precision diagnostics. Additionally, his studies address the genetic and cellular characteristics associated with poor therapeutic responses in leukemia patients, as well as the role of specific genes and proteins in the progression of these diseases. His work is pivotal in advancing precision medicine and improving diagnostic and therapeutic strategies for acute leukemia.

Aliases

T. Fioretos, Thoas Fioretos

Publication and Citation Metrics

Metric	Value
Total Citation Count	8229
H-index	49
Total Number of Papers	219

Publications:

Inducing synthetic lethality for selective targeting of acute myeloid leukemia cells harboring STAG2 mutations

DOI: 10.1101/2022.02.18.479480

Year: 2022

N-terminus DUX4-immunohistochemistry is a reliable methodology for the diagnosis of DUX4-fused B-lymphoblastic leukemia/lymphoma (N-terminus DUX4 IHC for DUX4-fused B-ALL).

DOI: 10.1002/gcc.23033

Year: 2022

A Study Protocol for Validation and Implementation of Whole-Genome and -Transcriptome Sequencing as a Comprehensive Precision Diagnostic Test in Acute Leukemias

DOI: 10.3389/fmed.2022.842507

Year: 2022

High CD34 surface expression in BCP-ALL predicts poor induction therapy response and is associated with altered expression of genes related to cell migration and adhesion.

DOI: 10.1002/1878-0261.13207

Year: 2022

Transcriptional profiling demonstrates altered characteristics of CD8+ cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia.

DOI: 10.1002/cam4.4661

Year: 2022

Single‐cell sequencing in translational cancer research and challenges to meet clinical diagnostic needs

DOI: 10.1002/gcc.22944

Year: 2021

[Precision diagnostics and therapy in hematological malignancies].

DOI:

Year: 2021

Transcriptomics paving the way for improved diagnostics and precision medicine of acute leukemia.

DOI: 10.1016/j.semcancer.2021.09.013

Year: 2021

In Vivo crispr Screening Identifies GLUT1 As a Key Metabolic Regulator of MLL-AF9-Driven Acute Myeloid Leukemia

DOI: 10.1182/blood-2021-152371

Year: 2021

Trailblazing Precision Medicine in Europe: a joint view by Genomic Medicine Sweden and the Centers for Personalized Medicine, ZPM, in Germany.

DOI: 10.1016/j.semcancer.2021.05.026

Year: 2021

How do Viral Vectors Work?

What Role does Genetic Counseling Play?

What Preventive Measures Can Be Taken?

What Are the Applications of Sanger Sequencing in Genetic Research?

What are the Symptoms of Sickle Cell Anemia?

Why is Cellular Heterogeneity Important in Genetics?

What are the advantages of using ZFNs?

What are the Options for Individuals with BRCA1 or BRCA2 Mutations?

What Research is Being Done on Sickle Cell Anemia?

How Do Nucleotide Mutations Occur?

Partnered Content Networks

Relevant Topics